Financial Contrast: Invivyd (NASDAQ:IVVD) and Arcus Biosciences (NYSE:RCUS)

Arcus Biosciences (NYSE:RCUS) and Invivyd (NASDAQ:IVVD) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, institutional ownership, dividends, valuation and earnings.

Risk & Volatility

Arcus Biosciences has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500.

Profitability

This table compares Arcus Biosciences and Invivyd’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-393.16%	-89.54%	-45.61%
Invivyd	-183.90%	-59.73%	-48.97%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Arcus Biosciences and Invivyd, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1	3	12	0	2.69
Invivyd	1	2	3	0	2.33

Arcus Biosciences presently has a consensus price target of $38.55, indicating a potential upside of 74.69%. Invivyd has a consensus price target of $10.00, indicating a potential upside of 1,516.55%. Given Invivyd’s higher possible upside, analysts plainly believe Invivyd is more favorable than Arcus Biosciences.

Valuation and Earnings

This table compares Arcus Biosciences and Invivyd”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247.00 million	11.37	-$353.00 million	($3.90)	-5.66
Invivyd	$53.43 million	3.41	-$52.49 million	($0.33)	-1.87

Invivyd has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 7.6% of Arcus Biosciences shares are held by insiders. Comparatively, 12.2% of Invivyd shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Invivyd beats Arcus Biosciences on 8 of the 14 factors compared between the two stocks.

About Arcus Biosciences

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

About Invivyd

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.